Klebsiella in inflammatory bowel disease
A specific clade of Klebsiella pneumoniae (Kp) is enriched in the gut of inflammatory bowel disease (IBD) patients and is associated with disease flares; when these strains colonize colitis-prone or gnotobiotic mice they drive intestinal inflammation (in part via Th17/Th1 cell induction and epithelial inflammasome signaling such as caspase-11/IL-18). Because this is a single pathobiont rather than a broad dysbiosis, broad-spectrum antibiotics are a poor fit — they collaterally damage protective commensals and breed resistance in an organism already prone to carbapenem resistance. Bacteriophages are well suited here precisely because they are exquisitely strain-specific: a lytic phage cocktail can subtract the offending Kp from a complex community while leaving the rest of the microbiome intact. This makes phages a leading 'precision microbiome' modality for the Klebsiella-in-IBD problem, with an oral, gut-targeted route that matches the site of disease.
How phages act here
Mechanism
Lytic phages bind specific Kp surface receptors (capsular polysaccharide and LPS/O-antigen), inject their genome, hijack the host to replicate, and lyse the cell — killing only the bacteria displaying the matching receptor, so neighboring commensals are spared. Because single phages have narrow host range and Kp readily mutates its capsule to escape, the validated approach is a rationally assembled cocktail (Federici et al. used a five-phage consortium combining phages active against both phage-sensitive and escape-mutant Kp) to broaden coverage and suppress resistance emergence; receptor-escape mutants are often less virulent (capsule loss), a fitness trade-off. Many Kp phages also encode capsule depolymerases that degrade the polysaccharide capsule and biofilm matrix, improving penetration of gut-adherent and biofilm-embedded Kp. Phage-antibiotic synergy (PAS) is an active adjunct strategy against multidrug-resistant Kp, and engineered/CRISPR-Cas 'sequence-specific antimicrobial' phage approaches are being explored to make killing even more targeted and to re-sensitize resistant strains, though for the IBD indication the clinically advanced work uses natural lytic cocktails delivered orally with gastric-acid protection.
Where it stands
Current evidence
Evidence is strong preclinical plus early-phase human safety, not yet proven efficacy in IBD patients. The landmark study (Federici et al., Cell 2022) profiled ~537 IBD patients across four countries, identified an IBD-flare-associated Kp clade, and showed a five-phage cocktail (phages including MCoc5c, 8M-7, 1.2-3s, KP2-5-1, PKP-55) reduced Kp burden and attenuated colitis/inflammation in colonized and colitis-prone mice; it also demonstrated phage viability and safety through an artificial human gut and in healthy volunteers. A follow-up (Ichikawa, Nakamoto, Kredo-Russo et al., Nature Communications 2023) showed a Kp-targeting phage cocktail reduced fecal Kp and lessened hepatobiliary injury/fibrosis in mouse models of primary sclerosing cholangitis (PSC), the IBD-comorbid liver disease. Clinically, BiomX (Weizmann Institute spin-out, in collaboration with the Elinav lab) advanced this program as oral BX002/BX003: a Phase 1a study in healthy volunteers (reported 2021) found the orally delivered Kp phages safe and well tolerated with no serious adverse events and delivery of ~10^10 PFU of viable phage to the gut, supporting progression to a Phase 1b/2a Kp-reduction study (BX003). As of 2026 there is no published Phase 2 efficacy readout in IBD patients, so the indication rests on robust mechanism + animal efficacy + human safety/PK.
Evidence confidence: medium
The data
Key studies & trials
- Federici S, Kredo-Russo S, Valdés-Mas R, Kviatcovsky D, Weinstock E, et al. Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation. Cell. 2022 Aug 4;185(16):2879-2898.e24. ↗
- Ichikawa M, Nakamoto N, Kredo-Russo S, et al. Bacteriophage therapy against pathological Klebsiella pneumoniae ameliorates the course of primary sclerosing cholangitis. Nature Communications. 2023;14:3261. ↗
- Federici S, et al. (commentary: Sausset R, De Sordi L). Host happy hour: Phage cocktail targets IBD-associated microbes. Cell Host & Microbe. 2022 Aug 10;30(8):1066-1068. ↗
Who is working on it
Programs & centers
The possibility
If the early human safety and pharmacokinetic data translate into Phase 2 efficacy, an oral 'designer' phage cocktail could become the first treatment that surgically deletes a single inflammation-driving Klebsiella strain from a patient's gut while leaving the protective microbiome untouched — a true precision-medicine alternative to immunosuppression. One can imagine a diagnostic step that sequences a flaring patient's Kp clade, followed by a matched, capsule-depolymerase-armed phage cocktail (potentially CRISPR-enhanced and self-amplifying at the site of infection) taken as a capsule. Extending the same playbook from IBD to the comorbid liver disease PSC hints at a broader future in which gut-targeted phages quiet not only the bowel but the downstream organs that share its microbial drivers.